Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02516150 · ClinicalTrials.gov registry record · Phase 4
Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon
A Phase 4 study of Type 1 Diabetes Mellitus, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT02516150 is a Phase 4 study of Type 1 Diabetes Mellitus that has completed, run by Massachusetts General Hospital. The registered enrollment target is 26 participants, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02516150, a Phase 4 study of Type 1 Diabetes Mellitus, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will test the hypothesis that a BAC (blood alcohol content) of 0.1% will not significantly alter the anti-hypoglycemic effect of mico-dose glucagon in individuals with type 1 diabetes.
Conditions Studied
Interventions
- DRUG Ethanol
- DRUG Glucagon
Study Locations (1)
Massachusetts
- Massachusetts General Hospital Diabetes Research Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2016-03 |
| Est. Completion | 2017-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02516150
The ClinicalTrials.gov registry entry for NCT02516150 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (81% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Ethanol is the first listed.
NCT02516150 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02516150 about?
NCT02516150 is a clinical study titled "Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon". This study will test the hypothesis that a BAC (blood alcohol content) of 0.1% will not significantly alter the anti-hypoglycemic effect of mico-dose glucagon in individuals with type 1 diabetes.
What is the current status of trial NCT02516150?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2016-03. Estimated completion is 2017-06.
What conditions does trial NCT02516150 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT02516150?
The interventions under investigation include: Ethanol (DRUG), Glucagon (DRUG).
Who is sponsoring clinical trial NCT02516150?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02516150 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dapagliflozin Plus Pioglitazone in T1DM
RECRUITING · Phase 4
-
CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)
COMPLETED · Phase 4
-
The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children
COMPLETED · Phase 4
-
Detemir: Role in Type 1 Diabetes
COMPLETED · Phase 4
-
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
RECRUITING · Phase 2
-
Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.